Drug Type Bispecific antibody |
Synonyms- |
Target |
Mechanism CD1d inhibitors(CD1d antigens inhibitors), TCR antagonists(T-cell receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | NL | 01 Nov 2020 | |
Neoplasms | Preclinical | NL | 01 Nov 2020 |